PUBLISHER: The Business Research Company | PRODUCT CODE: 1750976
PUBLISHER: The Business Research Company | PRODUCT CODE: 1750976
Drug-delivery technology refers to advanced systems and devices designed to deliver pharmaceutical compounds to specific areas of the body in a controlled and efficient manner. These technologies aim to improve the therapeutic effects of medications, minimize side effects, and enhance patient compliance through various delivery methods, including oral, injectable, transdermal, and implantable systems.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of drug-delivery technology include oral, injectable, topical, ocular, nasal, pulmonary, transmucosal, and implantable methods. Oral drug delivery involves taking medication via the mouth, typically in the form of tablets or capsules. This method offers convenience and improved effectiveness by utilizing enhanced solubility and absorption technologies. It is used in treating a range of conditions, including cardiovascular diseases, oncology, urology, diabetes, central nervous system (CNS) disorders, ophthalmology, and infections, and is applied in settings such as hospitals, clinics, diagnostic centers, home care, and others.
The drug-delivery technology market research report is one of a series of new reports from The Business Research Company that provides drug-delivery technology market statistics, including the drug-delivery technology industry global market size, regional shares, competitors with the drug-delivery technology market share, detailed drug-delivery technology market segments, market trends, and opportunities, and any further data you may need to thrive in the drug-delivery technology industry. This drug-delivery technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The drug-delivery technology market size has grown rapidly in recent years. It will grow from$48.95 billion in 2024 to $54.74 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to the rising demand for targeted drug delivery systems, the increasing prevalence of chronic diseases, the growing adoption of biologics, the higher incidence of respiratory diseases, and the growing popularity of needle-free drug delivery solutions.
The drug-delivery technology market size is expected to see rapid growth in the next few years. It will grow to$84.46 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to the rise in personalized medicine, an increasing number of regulatory approvals, the growing adoption of smart drug delivery systems, a preference for biodegradable drug carriers, and the rising prevalence of rare diseases. Key trends expected in the forecast period include applications of nanotechnology, patient-centric delivery systems, advancements in inhalation therapies, the use of bioprinting for drug delivery, and the integration of artificial intelligence.
The growing prevalence of chronic diseases is expected to accelerate the growth of the drug-delivery technology market. Chronic diseases are long-term medical conditions that typically progress slowly and require ongoing management. The rise in chronic diseases is largely attributed to sedentary lifestyles, which reduce physical activity and contribute to obesity and other related health issues. Drug-delivery technology plays a critical role in managing chronic diseases by enabling targeted drug delivery, controlled release, improved bioavailability, and reduced side effects, ultimately enhancing treatment effectiveness, patient adherence, and disease management. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that the age-standardized death rate due to chronic conditions increased from 459 per 100,000 people in 2021 to 490 per 100,000 people in 2022. As a result, the increasing prevalence of chronic diseases is driving the growth of the drug-delivery technology market.
Leading companies in the drug-delivery technology market are focusing on the development of innovative products such as prefilled injection devices to improve patient convenience, enhance dosing accuracy, and ensure safer drug administration. A prefilled injection device is a medical device that comes preloaded with a specific dose of medication, eliminating the need for manual drug filling before use. For example, in February 2023, Phillips-Medisize LLC, a US-based medical equipment manufacturer, launched a new disposable pen injector designed for high-volume manufacturing. The injector features a compact and flexible design with customizable dosing and push-button colors, supporting multiple therapies such as diabetes, fertility, growth hormones, obesity, and osteoporosis. This device aims to help pharmaceutical companies speed up market entry by offering a cost-effective, ready-to-use solution, while also reducing commercialization costs and risks.
In June 2022, Kindeva Drug Delivery L.P., a US-based pharmaceutical manufacturing company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition is intended to enhance Kindeva Drug Delivery's inhalation formulation outsourcing capabilities, offering a comprehensive portfolio of respiratory delivery expertise and accelerating its one-stop contract development and manufacturing organization (CDMO) approach to support clients from feasibility to commercialization. iPharma Labs Inc., based in the US, specializes in inhalation therapies and drug delivery technologies.
Major players in the drug-delivery technology market are Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc, Novartis AG, GlaxoSmithKline Plc., Cipla Limited, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici S.p.A., United Therapeutics Corporation, Mallinckrodt Pharmaceuticals Plc., Lupin Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Alkermes plc., Halozyme Therapeutics Inc., Sunovion Pharmaceuticals Inc., Circassia Pharmaceuticals Plc.
North America was the largest region in the drug-delivery technology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in drug-delivery technology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the drug-delivery technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The drug-delivery technology market consists of revenues earned by entities by providing services such as custom drug formulation, controlled-release drug delivery systems, injectable drug delivery solutions, nanosystems for drug delivery, and transdermal drug delivery systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The drug-delivery technology market includes sales of microneedle patches, implantable pumps, oral delivery systems, biodegradable drug delivery devices, and liposome-based drug delivery systems. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Drug-Delivery Technology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on drug-delivery technology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for drug-delivery technology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The drug-delivery technology market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.